JP Morgan Chase
BMRN icon

JP Morgan Chase’s BioMarin Pharmaceuticals BMRN Stock Holding History

JP Morgan Chase’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64M Hold
30,000
– – ﹤0.01% 4258
2025
Q4 		$1.78M Buy
+30,000
New +$1.63M ﹤0.01% 4165
2024
Q1 		– Sell
-50,200
Closed -$4.84M – 7435
2023
Q4 		$4.84M Buy
+50,200
New +$4.44M ﹤0.01% 3117
2023
Q3 		– Sell
-77,000
Closed -$6.67M – 7469
2023
Q2 		$6.67M Buy
77,000
+26,200
+52% +$2.47M ﹤0.01% 2646
2023
Q1 		$4.94M Sell
50,800
-34,200
-40% -$3.55M ﹤0.01% 2836
2022
Q4 		$8.8M Buy
+85,000
New +$7.98M ﹤0.01% 2373
2022
Q3 		– Sell
-103,700
Closed -$8.59M – 6465
2022
Q2 		$8.59M Buy
+103,700
New +$8.26M ﹤0.01% 2294
2021
Q2 		– Sell
-43,400
Closed -$3.28M – 6346
2021
Q1 		$3.28M Sell
43,400
-310,000
-88% -$25.3M ﹤0.01% 3320
2020
Q4 		$31M Buy
353,400
+242,900
+220% +$19.3M ﹤0.01% 1317
2020
Q3 		$8.4M Buy
110,500
+85,700
+346% +$8.67M ﹤0.01% 2179
2020
Q2 		$3.06M Sell
24,800
-75,200
-75% -$7.47M ﹤0.01% 2820
2020
Q1 		$8.45M Buy
100,000
+73,000
+270% +$6.29M ﹤0.01% 1873
2019
Q4 		$2.28M Buy
+27,000
New +$2.04M ﹤0.01% 3292
2019
Q2 		– Sell
-14,100
Closed -$1.25M – 5769
2019
Q1 		$1.25M Sell
14,100
-16,300
-54% -$1.51M ﹤0.01% 3667
2018
Q4 		$2.59M Sell
30,400
-19,600
-39% -$1.86M ﹤0.01% 3104
2018
Q3 		$4.85M Sell
50,000
-44,000
-47% -$4.39M ﹤0.01% 2773
2018
Q2 		$8.86M Buy
94,000
+44,000
+88% +$3.85M ﹤0.01% 2243
2018
Q1 		$4.05M Hold
50,000
– – ﹤0.01% 2754
2017
Q4 		$4.46M Buy
+50,000
New +$4.35M ﹤0.01% 2770
2016
Q4 		– Sell
-60,000
Closed -$5.55M – 4998
2016
Q3 		$5.55M Buy
+60,000
New +$5.65M ﹤0.01% 2176
2015
Q3 		– Sell
-4,300
Closed -$588K – 3921
2015
Q2 		$588K Buy
4,300
+1,200
+39% +$149K ﹤0.01% 3505
2015
Q1 		$386K Buy
+3,100
New +$328K ﹤0.01% 3630

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's BMRN Position: Q1 2026 in Review

JP Morgan Chase increased its BioMarin Pharmaceuticals (BMRN) stake by 21% in Q1 2026, buying an estimated $5.7M and bringing the position to 557,836 shares worth $30.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1720.

JP Morgan Chase first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $590M in Q4 2015. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • JP Morgan Chase held 557,836 shares of BioMarin Pharmaceuticals worth $30.6M as of Q1 2026.
  • JP Morgan Chase bought 97,831 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $5.7M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1720 holding.
  • JP Morgan Chase first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's BioMarin Pharmaceuticals position peaked at $590M in Q4 2015.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.